Illumina (ILMN) to Release Earnings on Tuesday

Illumina (NASDAQ:ILMN) is scheduled to be announcing its earnings results after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of $0.11 per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.05. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.05 billion. During the same quarter in the prior year, the business earned $0.08 EPS. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. On average, analysts expect Illumina to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Illumina Stock Down 3.8 %

ILMN opened at $117.70 on Monday. The stock has a market capitalization of $18.75 billion, a price-to-earnings ratio of -14.44 and a beta of 1.15. The firm has a 50 day moving average price of $111.29 and a 200-day moving average price of $123.52. Illumina has a twelve month low of $89.00 and a twelve month high of $195.64. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Barclays lifted their price objective on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. Evercore ISI cut their price target on Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a report on Tuesday, June 11th. Citigroup raised Illumina from a “neutral” rating to a “buy” rating and set a $140.00 price objective on the stock in a research note on Wednesday, July 10th. TD Cowen reduced their price objective on shares of Illumina from $140.00 to $122.00 and set a “hold” rating for the company in a research note on Thursday, June 6th. Finally, Robert W. Baird increased their target price on Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $158.57.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.